Minocycline is cytoprotective in human trabecular meshwork cells and optic nerve head astrocytes by increasing expression of XIAP, survivin, and Bcl-2

Clinical Ophthalmology

Volumn 4, Issue 1, 2010, Pages 591-604

  Kernt, Marcus ^a   Neubauer, Aljoscha S ^a   Eibl, Kirsten H ^a   Wolf, Armin ^a   Ulbig, Michael W ^a   Kampik, Anselm ^a   Hirneiss, Cristoph ^a  

^a UNIVERSITY OF MUNICH   (Germany)

Author keywords

Apoptosis; Glaucoma; Minocycline; Optic nerve head astrocytes; Trabecular meshwork

Indexed keywords

EID: 77956124441     PISSN: 11775467     EISSN: 11775483     Source Type: Book Series    
DOI: 10.2147/opth.s11216     Document Type: Article

References (68)

1. Van Buskirk EM, Cioffi GA. Glaucomatous optic neuropathy. Am J Ophthalmol. 1992;113:447-452.
2. World Health Organization. Magnitude and causes of visual impairment. Fact Sheet Number 282: World Health Organization; 2004. Available at: http://www.who.int/mediacentre/factsheets/fs282/en/. Accessed May 12, 2010.
3. Quigley HA, Green WR. The histology of human glaucoma cupping and optic nerve damage: Clinicopathologic correlation in 21 eyes. Ophthalmology. 1979;86:1803-1830.
4. Goldberg LD. Clinical guidelines for the treatment of glaucoma. Manag Care. 2002;11:16-24.
5. Kass MA, Heuer DK, Higginbotham EJ, et al. The Ocular Hypertension Treatment Study: A randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol. 2002;120:701-13; discussion 829-830.
6. Heijl A, Leske MC, Bengtsson B, Hyman L, Hussein M. Reduction of intraocular pressure and glaucoma progression: Results from the Early Manifest Glaucoma Trial. Arch Ophthalmol. 2002;120:1268-1279.
7. Krakau CE. Intraocular pressure elevation - cause or effect in chronic glaucoma? Ophthalmologica. 1981;182:141-147.
8. Bonomi L, Marchini G, Marraffa M, Morbio R. The relationship between intraocular pressure and glaucoma in a defined population. Data from the Egna-Neumarkt Glaucoma Study. Ophthalmologica. 2001;215:34-38.
9. Alvarado J, Murphy C, Juster R. Trabecular meshwork cellularity in primary open-angle glaucoma and nonglaucomatous normals. Ophthalmology. 1984;91:564-579.
10. Rohen JW, Lutjen-Drecoll E, Flugel C, Meyer M, Grierson I. Ultrastructure of the trabecular meshwork in untreated cases of primary open-angle glaucoma (POAG). Exp Eye Res. 1993;56: 683-692.
11. Veach J. Functional dichotomy: Glutathione and vitamin E in homeostasis relevant to primary open-angle glaucoma. Br J Nutr. 2004;91: 809-829.
12. Findl O, Rainer G, Dallinger S, et al. Assessment of optic disk blood flow in patients with open-angle glaucoma. Am J Ophthalmol. 2000; 130:589-596.
13. Butt Z, O'Brien C, McKillop G, Aspinall P, Allan P. Color Doppler imaging in untreated high- and normal-pressure open-angle glaucoma. Invest Ophthalmol Vis Sci. 1997;38:690-696.
14. Ferreira SM, Lerner SF, Brunzini R, Evelson PA, Llesuy SF. Oxidative stress markers in aqueous humor of glaucoma patients. Am J Ophthalmol. 2004;137:62-69.
15. Levin LA, Clark JA, Johns LK. Effect of lipid peroxidation inhibition on retinal ganglion cell death. Invest Ophthalmol Vis Sci. 1996;37: 2744-2749.
16. Sacca SC, Pascotto A, Camicione P, Capris P, Izzotti A. Oxidative DNA damage in the human trabecular meshwork: Clinical correlation in patients with primary open-angle glaucoma. Arch Ophthalmol. 2005;123:458-463.
17. Fleenor DL, Shepard AR, Hellberg PE, Jacobson N, Pang IH, Clark AF. TGFbeta2-induced changes in human trabecular meshwork: Implications for intraocular pressure. Invest Ophthalmol Vis Sci. 2006;47: 226-234.
18. Min SH, Lee TI, Chung YS, Kim HK. Transforming growth factor-beta levels in human aqueous humor of glaucomatous, diabetic and uveitic eyes. Korean J Ophthalmol. 2006;20:162-165.
19. Nickells RW. Apoptosis of retinal ganglion cells in glaucoma: An update of the molecular pathways involved in cell death. Surv Ophthalmol. 1999;43 Suppl 1:S151-S161.
20. Garcia-Valenzuela E, Shareef S, Walsh J, Sharma SC. Programmed cell death of retinal ganglion cells during experimental glaucoma. Exp Eye Res. 1995;61:33-44.
21. Kerrigan LA, Zack DJ, Quigley HA, Smith SD, Pease ME. TUNELpositive ganglion cells in human primary open-angle glaucoma. Arch Ophthalmol. 1997;115:1031-1035.
22. Quigley HA, Nickells RW, Kerrigan LA, Pease ME, Thibault DJ, Zack DJ. Retinal ganglion cell death in experimental glaucoma and after axotomy occurs by apoptosis. Invest Ophthalmol Vis Sci. 1995;36: 774-786.
23. Cao Y, Wei H, Pfaffl M, Da B, Li Z. Apoptosis of human trabecular meshwork cells induced by transforming growth factor-beta2 in vitro. J Huazhong Univ Sci Technolog Med Sci. 2004;24:87-89, 94.
24. Ziangirova GG, Antonova OV. Lipid peroxidation in the pathogenesis of primary open-angle glaucoma. Vestn Oftalmol. 2003;119:54-55. Russian.
25. Aronson AL. Pharmacotherapeutics of the newer tetracyclines. J Am Vet Med Assoc. 1980;176:1061-1068.
26. Poirier RH, Ellison AC. Ocular penetration of orally administered minocycline. Ann Ophthalmol. 1979;11:1859-1861.
27. Klein NC, Cunha BA. Tetracyclines. Med Clin North Am. 1995;79: 789-801.
28. Ryan ME, Greenwald RA, Golub LM. Potential of tetracyclines to modify cartilage breakdown in osteoarthritis. Curr Opin Rheumatol. 1996;8:238-247.
29. Wirostko E, Wirostko WJ, Wirostko BM. Age-related macular degeneration is an inflammatory disease possibly treatable with minocycline. Acta Ophthalmol Scand. 2004;82:243-244.
30. Chen M, Ona VO, Li M, et al. Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease. Nat Med. 2000;6:797-801.
31. Yrjanheikki J, Keinanen R, Pellikka M, Hokfelt T, Koistinaho J. Tetracyclines inhibit microglial activation and are neuroprotective in global brain ischemia. Proc Natl Acad Sci U S A. 1998;95:15769-15774.
32. Zhu S, Stavrovskaya IG, Drozda M, et al. Minocycline inhibits cytochrome c release and delays progression of amyotrophic lateral sclerosis in mice. Nature. 2002;417:74-78.
33. Sanchez Mejia RO, Ona VO, Li M, Friedlander RM. Minocycline reduces traumatic brain injury-mediated caspase-1 activation, tissue damage, and neurological dysfunction. Neurosurgery. 2001;48:1393-9; discussion 1399-1401.
34. Popovic N, Schubart A, Goetz BD, Zhang SC, Linington C, Duncan ID. Inhibition of autoimmune encephalomyelitis by a tetracycline. Ann Neurol. 2002;51:215-223.
35. Du Y, Ma Z, Lin S, et al. Minocycline prevents nigrostriatal dopaminergic neurodegeneration in the MPTP model of Parkinson's disease. Proc Natl Acad Sci U S A. 2001;98: 14669-14674.
36. Kraus RL, Pasieczny R, Lariosa-Willingham K, Turner MS, Jiang A, Trauger JW. Antioxidant properties of minocycline: Neuroprotection in an oxidative stress assay and direct radical-scavenging activity. J Neurochem. 2005;94:819-827.
37. Tikka T, Fiebich BL, Goldsteins G, Keinanen R, Koistinaho J. Minocycline, a tetracycline derivative, is neuroprotective against excitotoxicity by inhibiting activation and proliferation of microglia. J Neurosci. 2001;21:2580-2588.
38. Wang J, Wei Q, Wang CY, Hill WD, Hess DC, Dong Z. Minocycline up-regulates Bcl-2 and protects against cell death in mitochondria. J Biol Chem. 2004;279:19948-19954.
39. Levkovitch-Verbin H, Kalev-Landoy M, Habot-Wilner Z, Melamed S. Minocycline delays death of retinal ganglion cells in experimental glaucoma and after optic nerve transection. Arch Ophthalmol. 2006; 124:520-526.
40. Kernt M, Kampik A. Intraocular caspofungin: In vitro safety profile for human ocular cells. Mycoses. Feb 19, 2010. [Epub ahead of print].
41. Kernt M, Liegl RG, Rueping J, et al. Sorafenib protects human optic nerve head astrocytes from light-induced overexpression of vascular endothelial growth factor, platelet-derived growth factor, and placenta growth factor. Growth Factors. Feb 19, 2010. [Epub ahead of print].
42. Kernt M, Neubauer AS, Ulbig MW, Kampik A, Welge-Lussen U. In vitro safety of intravitreal moxifloxacin for endophthalmitis treatment. J Cataract Refract Surg. 2008;34:480-488.
43. Siegner A, May CA, Welge-Lussen UW, Bloemendal H, Lutjen- Drecoll E. Alpha B-crystallin in the primate ciliary muscle and trabecular meshwork. Eur J Cell Biol. 1996;71:165-169.
44. Welge-Lussen U, Eichhorn M, Bloemendal H, Lutjen-Drecoll E. Classification of human scleral spur cells in monolayer culture. Eur J Cell Biol. 1998;75:78-84.
45. Mosmann T. Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays. J Immunol Methods. 1983;65:55-63.
46. Welge-Lussen U, May CA, Eichhorn M, Bloemendal H, Lutjen-Drecoll E. Alpha B-crystallin in the trabecular meshwork is inducible by transforming growth factor-beta. Invest Ophthalmol Vis Sci. 1999; 40:2235-2241.
47. Kahn MG, Giblin FJ, Epstein DL. Glutathione in calf trabecular meshwork and its relation to aqueous humor outflow facility. Invest Ophthalmol Vis Sci. 1983;24:1283-1287.
48. De La Paz MA, Epstein DL. Effect of age on superoxide dismutase activity of human trabecular meshwork. Invest Ophthalmol Vis Sci. 1996;37:1849-1853.
49. Levine AJ. p53, the cellular gatekeeper for growth and division. Cell. 1997;88:323-331.
50. McKinnon SJ, Lehman DM, Kerrigan-Baumrind LA, et al. Caspase activation and amyloid precursor protein cleavage in rat ocular hypertension. Invest Ophthalmol Vis Sci. 2002;43:1077-1087.
51. Miyashita T, Reed JC. Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell. 1995;80:293-299.
52. Miyashita T, Harigai M, Hanada M, Reed JC. Identification of a p53- dependent negative response element in the bcl-2 gene. Cancer Res. 1994;54:3131-3135.
53. Hockenbery DM. The bcl-2 oncogene and apoptosis. Semin Immunol. 1992;4:413-420.
54. Deveraux QL, Takahashi R, Salvesen GS, Reed JC. X-linked IAP is a direct inhibitor of cell-death proteases. Nature. 1997;388:300-304.
55. Holcik M, Gibson H, Korneluk RG. XIAP: Apoptotic brake and promising therapeutic target. Apoptosis. 2001;6:253-261.
56. Sasaki T, Lopes MB, Hankins GR, Helm GA. Expression of survivin, an inhibitor of apoptosis protein, in tumors of the nervous system. Acta Neuropathol (Berl). 2002;104:105-109.
57. McKinnon SJ, Lehman DM, Tahzib NG, et al. Baculoviral IAP repeatcontaining- 4 protects optic nerve axons in a rat glaucoma model. Mol Ther. 2002;5:780-787.
58. Petrin D, Baker A, Coupland SG, et al. Structural and functional protection of photoreceptors from MNU-induced retinal degeneration by the X-linked inhibitor of apoptosis. Invest Ophthalmol Vis Sci. 2003;44: 2757-2763.
59. Suzuki A, Ito T, Kawano H, et al. Survivin initiates procaspase 3/p21 complex formation as a result of interaction with Cdk4 to resist Fas- mediated cell death. Oncogene. 2000;19:1346-1353.
60. Suzuki A, Hayashida M, Ito T, et al. Survivin initiates cell cycle entry by the competitive interaction with Cdk4/p16(INK4a) and Cdk2/cyclin E complex activation. Oncogene. 2000;19:3225-3234.
61. Shin S, Sung BJ, Cho YS, et al. An anti-apoptotic protein human survivin is a direct inhibitor of caspase-3 and -7. Biochemistry. 2001;40: 1117-1123.
62. Neufeld AH. Nitric oxide: A potential mediator of retinal ganglion cell damage in glaucoma. Surv Ophthalmol. 1999;43 Suppl 1: S129-S135.
63. Kumar DM, Agarwal N. Oxidative stress in glaucoma: A burden of evidence. J Glaucoma. 2007;16:334-343.
64. Bjornberg A, Roupe G. Susceptibility to infections during long-term treatment with tetracyclines in acne vulgaris. Dermatologica. 1972;145: 334-337.
65. Margolis DJ. Antibiotics, acne, and upper respiratory tract infections. LDI Issue Brief. 2006;11:1-4.
66. Goulden V, Glass D, Cunliffe WJ. Safety of long-term high-dose minocycline in the treatment of acne. Br J Dermatol. 1996;134:693-695.
67. Topouzis F, Tranos P, Koskosas A, et al. Risk of sudden visual loss following filtration surgery in end-stage glaucoma. Am J Ophthalmol. 2005;140:661-666.
68. Agar A, Li S, Agarwal N, Coroneo MT, Hill MA. Retinal ganglion cell line apoptosis induced by hydrostatic pressure. Brain Res. 2006; 1086: 191-200.